A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Required: EGFR sensitizing mutation (Exon 21-L858R and 19del)

documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del)

Required: HER2 (ERBB2) negative

breast cancer that is documented as HER2-negative

Required: EGFR no actionable genomic alterations

no actionable genomic alterations, such as EGFR mutations, anaplastic lymphoma kinase rearrangements, or other genomic alterations for which targeted molecular therapies are available

Required: ALK no actionable genomic alterations

no actionable genomic alterations, such as EGFR mutations, anaplastic lymphoma kinase rearrangements, or other genomic alterations for which targeted molecular therapies are available

Allowed: BRAF mutation

for participants with human gene that encodes a protein called B-Raf (BRAF) gene mutant melanoma, a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene inhibitor

Allowed: HER2 (ERBB2) expression positive

HER2-expression positive subgroup

Allowed: ESR1 negative

HR-negative or HR-positive

Allowed: PR (PGR) negative

HR-negative or HR-positive

Must have received: PD-1 inhibitor — advanced/metastatic melanoma

must have previously received a PD-1 or PD-L1 inhibitor

Must have received: BRAF inhibitor (vemurafenib, dabrafenib) — BRAF mutant melanoma

for participants with BRAF gene mutant melanoma, a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene inhibitor with or without mitogen-activated protein kinase protein inhibitor

Must have received: EGFR tyrosine kinase inhibitor — EGFR-mutant NSCLC

must include treatment with an approved EGFR Tyrosine Kinase Inhibitors (TKI), with at least one being a third-generation EGFR TKI

Must have received: platinum-based chemotherapy — NSCLC, cervical cancer

must have received platinum-based chemotherapy

Must have received: anti-PD-1 therapy — cervical cancer

with or without an anti-PD-(L)1 agent

Must have received: bevacizumab (bevacizumab) — cervical cancer

with or without an anti-PD-(L)1 agent and bevacizumab

Must have received: HER2-targeted therapy — HER2-positive gastric/GEJ cancer

including a HER2-targeted agent in accordance with local SoC

Cannot have received: topoisomerase I inhibitor (topotecan, irinotecan, deruxtecan)

history of intolerance to treatment with a topoisomerase I inhibitor or intolerance to an ADC that consists of a topoisomerase I inhibitor, including but not limited to topotecan, irinotecan, and deruxtecan

Cannot have received: anti-VEGF (bevacizumab, ramucirumab)

history of intolerance to treatment with an anti-VEFG, anti-PD-1/PDL-1, or similar substance, including, but not limited to, bevacizumab, ramucirumab, atezolizumab, pembrolizumab, nivolumab, or other related therapies

Cannot have received: anti-PD-1 therapy (atezolizumab, pembrolizumab, nivolumab)

history of intolerance to treatment with an anti-VEFG, anti-PD-1/PDL-1, or similar substance, including, but not limited to, bevacizumab, ramucirumab, atezolizumab, pembrolizumab, nivolumab, or other related therapies